Structure-free AI platform delivers picomolar leads while cutting wet-lab validation to 20-50 samples per round
Ainnocence Inc., an AI-driven pharmaceutical & material IP-generating platform company, today reported performance results from 75 completed protein design programs and announced that it is seeking licensing and partnering agreements for 28 antibody, bispecific and ADC programs that have generated positive preclinical data across oncology, immunology and metabolic indications.
Across 58 affinity maturation campaigns, Ainnocence's SentinusAI® platform succeeded in 53, a 91.4% program success rate, with only five campaigns failing to produce an improved binder. On novel targets attempted with no structural information and no prior binder, 9 of 17 de novo campaigns (53%) yielded validated hits.
Performance
without structure Unlike 3D
structure-dependent approaches, SentinusAI® predicts binding directly from
sequence, removing the requirement for a resolved co-crystal or predicted
complex. That design choice underpins both the platform's throughput and its
economics: Ainnocence reports a roughly 10,000-fold reduction in computational
cost relative to conventional 3D modeling workflows, a computation cycle of one
to two weeks per round, and capacity to run more than 100 programs
concurrently. The practical
effect is on the wet lab. Because each round is narrowed to 20-50 designs before
synthesis, partners test tens of molecules rather than thousands: ·
De novo design: 7.5% positive rate on round-1
zero-shot prediction, rising to 30% on round-2 reinforcement-learning iteration
·
Affinity
maturation: 21.5%
positive rate on round-1 zero-shot prediction, rising to 43.8% on round-2
iteration ·
Affinity gains
from tens- to thousands-fold over the parent molecule, with leads reaching
picomolar potency
Picomolar
leads across formats Delivered
programs span Fabs, scFvs, mAbs, bispecifics and ADC-enabling binders.
Of the campaigns with quantified KD readouts, 28 reached sub-nanomolar
affinity and seven reached 100 pM or better. Leading results include an
IL-15×IL-21 bispecific at approximately 0.09 pM on the IL-21 arm, a TNFα-OX40L
bispecific at 8.6 pM, an anti-C1q program at 1-20 pM and a TL1A×p40 bispecific
at 23 pM. An anti-VEGF scFv-IgG measured 27.8-34.6 pM by SPR, outperforming the
bevacizumab reference run in the same experiment.
Twenty-eight
programs available for licensing Ainnocence's
internal pipeline comprises 37 programs, of which 28 have produced positive
data and are now available for licensing or partnering, individually or as a
portfolio. Highlights include a TL1A×p40 bispecific (KD 0.16 nM; benchmark
duvakitug, Phase 3), an anti-IL-36R Fab with 13 of 21 matured variants binding
below the 1 pM detection limit (benchmark spesolimab-class HB-0034), an
anti-TROP2 ADC lead at 0.37-0.43 nM with confirmed internalization (benchmark
Trodelvy) and an anti-B7-H3 program at approximately 0.56 nM (benchmark
ifinatamab deruxtecan, Phase 2). Seven ADC-ready internalizing oncology targets
have been validated by FACS, and internalization assay and leads have expressed
at titers up to approximately 440 mg/L at greater than 99% SEC purity.
“The
number that matters to a partner is not how many molecules our model can score,
it is how many they have to make,”
said Dr.Lurong Pan, PhD, Founder and CEO of Ainnocence. “Twenty to fifty
designs per round, one to two weeks of compute and a 91.4% program success rate
across 58 maturation campaigns is a different operating model for antibody
discovery. And because we never depended on a resolved structure, the targets
other platforms set aside are the ones we take on.”
Collaborate
with Ainnocence Ainnocence is
seeking licensing and partnering relationships to advance the pipeline through
affinity finalization, ADC conjugation, in vivo efficacy and clinical
development. Additional non-confidential and confidential materials are
available on request.
About Ainnocence
Inc. Founded in
2021 and headquartered in California, Ainnocence is a next-generation
biotechnology company transforming drug discovery and synthetic biology through
AI-based, sequence-first engineering. Ainnocence’s self-evolving platform
evaluates up to 10 billion molecules spanning proteins, antibodies, small
molecules, nucleic acids, and chemical formulations within hours to weeks,
enabling rapid, multi-objective design across therapeutic, biological, and
chemical systems. By reducing R&D timelines and costs while increasing
success rates, Ainnocence empowers industry and academic partners to pursue
complex biological innovation with greater precision and control.
Contact: Dr. Lurong Pan,
PhD +1
205-249-7424 Visit
us on social media: LinkedIn | YouTube | X
